Table 1.
Predictive value of intrinsic subtype on OS by treatment arm.
| Subtype | Treatment arm | Distribution, n (%) | Events, n (%)a | Median OS estimate | Median OS 95% CI | HR estimate | HR 95% CI | P value |
|---|---|---|---|---|---|---|---|---|
| Luminal A | PBO | 221 (54) | 122 (55) | 54.6 | 48.3–66.2 | 0.75 | 0.58–0.96 | 0.021 |
| RIB | 319 (55) | 135 (42) | 68.0 | 61.5-NA | ||||
| Luminal B | PBO | 124 (30) | 79 (64) | 44.9 | 35.5–52.6 | 0.69 | 0.50–0.95 | 0.023 |
| RIB | 153 (26) | 75 (49) | 58.8 | 48.3–79.2 | ||||
| HER2E | PBO | 51 (12) | 39 (76) | 29.4 | 23.9–42.0 | 0.60 | 0.40–0.92 | 0.018 |
| RIB | 94 (16) | 59 (63) | 40.3 | 33.4–49.0 | ||||
| Basal-like | PBO | 14 (3) | 11 (79) | 21.2 | 12.8-NA | 1.92 | 0.81–4.53 | 0.137 |
| RIB | 14 (2) | 14 (100) | 19.0 | 10.7–33.2 |
Abbreviations: HER2E, human epidermal growth factor receptor 2–enriched; HR, hazard ratio; NA, not achieved; PBO, placebo; RIB, ribociclib.
aPercentage of patients within each row experiencing an event.